<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1385">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01773200</url>
  </required_header>
  <id_info>
    <org_study_id>P/2012/153</org_study_id>
    <nct_id>NCT01773200</nct_id>
  </id_info>
  <brief_title>Prognostic Value of Circulating Endothelial Progenitor Cells in Aneurysmal Subarachnoid Hemorrhage</brief_title>
  <acronym>EVAPROPEC</acronym>
  <official_title>Prognostic Value of Circulating Endothelial Progenitor Cells in Aneurysmal Subarachnoid Hemorrhage (Evaluation de l'intérêt Pronostic Des progéniteurs endothéliaux Circulants Dans l'hémorragie Sous-arachnoïdienne Par Rupture d'anévrysme cérébral)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Besancon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Besancon</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aneurysmal subarachnoid hemorrhage is a common and serious disease associated to a high rate
      of mortality and morbidity. Severe definitive neurological impairment can concern up to 30%
      of patients in relation with elevated intracranial pressure, hemorrhage recurrence and
      symptomatic cerebral arterial vasospasm. This latter complication is defined as a reversible
      reduction of cerebral artery's diameter occurring between the 4th and the 14th day after
      bleeding. Physiopathology is not well understood, but could involve endothelium, trough
      endothelial progenitor cells (EPC). Circulating EPC are bone marrow-derived cells with
      capacity of vasculogenesis and angiogenesis. EPC have been recognized playing a beneficial
      role in cardiovascular disease and ischemic stroke. EPC have never been studied in
      aneurysmal subarachnoid hemorrhage.

      The primary objective of this study is to compare the number of circulating endothelial
      progenitor cells between patients with a good neurological outcome (defined as a glasgow
      outcome scale = 1 or 2) and patients with a poor neurological outcome (glasgow outcome scale
      = 3, 4 or 5).

      Briefly, the number of circulating EPC will be measured at admission, and at day 3, 6, 10,
      14, 21 in each consecutive patient suffering aneurysmal subarachnoid hemorrhage and
      hospitalized in Teaching Hospital of Besançon (France). The neurological outcome will be
      measured one year after subarachnoid hemorrhage.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>endothelial progenitor cells count</measure>
    <time_frame>day 3 after bleeding</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Endothelial progenitor cells count</measure>
    <time_frame>day 0, 6, 10, 14, 21 after bleeding</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximal amplitude of variation of EPC count</measure>
    <time_frame>3 weeks after bleeding</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasmatic brain natriuretic peptide</measure>
    <time_frame>day 0, 3, 6, 10, 14, 21 after bleeding</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Glasgow Outcome Scale</measure>
    <time_frame>One year after bleeding</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Vasospasm occurence</measure>
    <time_frame>during the 3 weeks after bleeding</time_frame>
    <safety_issue>No</safety_issue>
    <description>Vasospasm will be defined as at less one segmental narrowing of a cerebral artery diagnosed on cerebral angiography (angio scanner, angio-MRI or 4 axes cerebral arteriography). Cerebral angiography will be done as necessary according to the occurence of the following situations
a clinical neurological deterioration unexplained by another cause
a mean arterial blood flow speed higher than 2 m/s assessed in cerebral arteries by transcranial doppler or a significant elevation of the mean arterial blood flow speed on two consecutive evaluations</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">92</enrollment>
  <condition>Aneurysmal Subarachnoid Hemorrhage</condition>
  <arm_group>
    <arm_group_label>Aneurysmal Subarachnoid Hemorrhage</arm_group_label>
    <description>Each consecutive patient suffering from aneurysmal subarachnoid hemorrhage</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Consecutive patients suffering from acute aneurysmal subarachnoid haemorrhage. .
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  recent(&lt; 24 h) aneurysmal subarachnoid hemorrhage

          -  written informed consent obtained from the patient or from close relatives

        Exclusion Criteria:

          -  refusal to participate

          -  Non-aneurysmal subarachnoid hemorrhage

          -  aneurysmal subarachnoid hemorrhage with estimated date of bleeding &gt; 24 h

          -  Chronic heart failure

          -  Chronic medication able to modify the plasmatic level of BNP

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sébastien Pili-Floury, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHRU de Besançon</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sébastien Pili-Floury, MD, PhD</last_name>
    <phone>+33 3 81 66 85 79</phone>
    <email>spilifloury@orange.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHRU de Besançon</name>
      <address>
        <city>Besançon</city>
        <zip>25000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <lastchanged_date>May 21, 2014</lastchanged_date>
  <firstreceived_date>January 18, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>endothelial progenitor cells</keyword>
  <keyword>aneurysmal subarachnoid hemorrhage</keyword>
  <keyword>vasospasm</keyword>
  <keyword>BNP</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Subarachnoid Hemorrhage</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
